Periodontal Ehlers–Danlos Syndrome: Disease-Characteristics Report

Executive summary

Periodontal Ehlers–Danlos syndrome (pEDS) is an ultra-rare, autosomal-dominant connective-tissue disorder caused by heterozygous pathogenic variants in C1R or C1S. Its defining manifestations are generalized absence of attached gingiva from childhood and severe, rapidly progressive periodontitis, often followed by premature tooth loss. Easy bruising, pretibial hemosiderotic plaques, skin fragility, distal joint hypermobility, hoarseness, vascular abnormalities, and usually asymptomatic cerebral white-matter disease may accompany the oral phenotype. Unlike most EDS subtypes, pEDS arises from dysregulated complement serine proteases rather than a primary collagen-gene defect. Functional evidence now indicates both constitutive complement activation and direct degradation of type-I collagen by activated C1s. No disease-modifying therapy or pEDS-specific interventional trial has been established; early molecular diagnosis, meticulous lifelong periodontal care, and complication-directed surveillance are current practice.

The strongest quantitative findings are summarized below.

Table: Compact synthesis of the principal clinical, pediatric, molecular and mechanistic evidence for periodontal Ehlers-Danlos syndrome. Sources: (kapfererseebacher2016periodontalehlersdanlossyndrome pages 3-5, kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2, angwin2023nonoralmanifestationsin pages 1-2, grobner2019c1rmutationstrigger pages 1-2, liao2022transcriptomeanalysisof pages 1-2, amberger2023degradationofcollagen pages 1-2)

1. Disease information

Definition and classification

pEDS is a Mendelian EDS subtype characterized by early severe periodontitis, lack of attached gingiva, and systemic connective-tissue fragility. It was formerly designated Ehlers–Danlos syndrome type VIII, EDS VIII, or periodontitis-type EDS. The discovery study described it as an autosomal-dominant disorder involving periodontal inflammation, premature tooth loss, joint laxity, and generally mild cutaneous abnormalities (kapfererseebacher2016periodontalehlersdanlossyndrome pages 3-5, kapfererseebacher2016periodontalehlersdanlossyndrome pages 1-2).

Identifiers

• MONDO: MONDO:0007527, “Ehlers-Danlos syndrome, periodontitis type.” Open Targets maps this disease to C1R and C1S (OpenTargets Search: periodontal Ehlers-Danlos syndrome-C1R,C1S).
• OMIM phenotype entries: 130080 and 617174, commonly corresponding to C1R- and C1S-associated periodontal EDS, respectively (amberger2023degradationofcollagen pages 1-2, grobner2019c1rmutationstrigger pages 1-2).
• Gene OMIM entries: C1R, MIM 613785; C1S, MIM 120580 (liao2022transcriptomeanalysisof pages 1-2, kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2).
• ICD: No specific ICD-10 code was established in the retrieved literature; it is ordinarily classified under Ehlers–Danlos syndrome/other specified congenital connective-tissue disorders. A dedicated ICD-11 entity was not verified.
• MeSH: No pEDS-specific MeSH heading was verified; indexing generally uses Ehlers-Danlos Syndrome and Periodontitis.

The evidence summarized here is aggregated disease-level evidence from published cohorts, family studies, and experimental work—not individual EHR-derived data. The principal discovery cohort included 19 families/107 examined individuals, with a molecular cause identified in 17 families and 93 mutation-positive individuals (kapfererseebacher2016periodontalehlersdanlossyndrome pages 3-5, kapfererseebacher2016periodontalehlersdanlossyndrome pages 1-2).

2. Etiology, risk, protection, and environment

Primary cause

The cause is a germline heterozygous pathogenic variant in C1R or C1S, usually a missense change or in-frame insertion/deletion affecting the complement C1 proteases. Fifteen of 17 molecularly solved families in the original series had C1R variants and two had C1S variants (kapfererseebacher2016periodontalehlersdanlossyndrome pages 1-2).

The molecular effect is better described as gain of abnormal proteolytic function or loss of physiological control, rather than simple haploinsufficiency. Heterozygous loss-of-function alleles are reportedly asymptomatic, whereas pEDS alleles cause abnormal processing, activation, and extracellular protease activity (grobner2019c1rmutationstrigger pages 1-2).

Risk factors

• Genetic: An affected parent or known familial C1R/C1S pathogenic variant is the principal risk factor. Each child of a heterozygous affected person has a theoretical 50% transmission risk.
• Family history: A clinically affected first-degree relative is a major diagnostic criterion (angwin2023nonoralmanifestationsin pages 1-2, kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2).
• Dental plaque/biofilm: Biofilm is not the primary cause, but it is an important downstream inflammatory trigger. Constitutively activated complement is hypothesized to produce disproportionate gingival inflammation after mild plaque accumulation (liao2022transcriptomeanalysisof pages 1-2, kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2).
• Age: Absence of attached gingiva is congenital or evident in childhood, while destructive periodontal disease is age-dependent and usually begins during childhood or adolescence (kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2).
• Temperature: Activated C1s completely degraded collagen I at 40°C in vitro. This is mechanistically interesting but does not establish fever, climate, or occupational heat as a clinical risk factor (amberger2023degradationofcollagen pages 1-2).

No reproducible sex, ethnic, dietary, smoking, toxicant, occupational, or infectious-agent susceptibility factor specific to pEDS has been demonstrated. Ordinary periodontal exposures, especially smoking and poor oral hygiene, should still be avoided because they plausibly add to an already highly susceptible periodontium, but pEDS-specific effect sizes are unavailable.

Protective factors and gene–environment interactions

No protective C1R/C1S alleles, modifier genes, or validated pharmacologic protective factors are known. The pediatric investigators concluded that early recognition may permit better dental hygiene and potentially prevent or delay early tooth loss, but controlled prevention data are absent (kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2). The best-supported gene–environment model is therefore:

C1R/C1S pathogenic variant → constitutive local protease/complement activity → exaggerated response to otherwise modest oral biofilm → accelerated periodontal inflammation and tissue destruction.

3. Phenotypes

Oral and dental manifestations

• Generalized lack of attached gingiva — clinical sign; HP:0000169 Gingival abnormality is a broad suggested term, supplemented by a proposed specific annotation “absence of attached gingiva.” It is present from childhood and appears highly penetrant. In a prospective study, all 12 variant-positive children had the finding and all seven non-carriers lacked it (kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2).
• Early-onset severe periodontitis — clinical sign; suggested HP:0000704 Periodontitis and HP:0006308 Premature loss of teeth. In the original mutation-positive cohort, periodontitis occurred in 99%; median diagnosis or first periodontal tooth loss was 14 years, range 2–35 years. First tooth loss occurred at 2–30 years and complete tooth loss at 14–48 years; 16% had prepubertal disease before age ten (kapfererseebacher2016periodontalehlersdanlossyndrome pages 3-5, wu2022periodontaldiseaseassociated pages 15-19, kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6).
• Gingival recession/thin fragile gingiva — clinical sign; suggested HP:0000169 Gingival abnormality. Gingival recession occurred in 98%, and thin or absent attached gingiva in 93% (kapfererseebacher2016periodontalehlersdanlossyndrome pages 3-5).
• Alveolar-bone and periodontal-support loss — progressive radiographic/clinical sign; suggested HP:0000704 Periodontitis. The affected unit includes gingiva, periodontal ligament, root cementum, and alveolar bone (kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2).

These oral manifestations impair chewing, speech, appearance, self-confidence, and maintenance of natural dentition. No pEDS-specific EQ-5D, SF-36, PROMIS, or validated oral-health quality-of-life dataset was identified.

Cutaneous, musculoskeletal, vascular, and other manifestations

Suggested HPO annotations include:

• Easy bruising — HP:0000978: 96% in the original cohort and 90% in a 2023 adult cohort; often present in childhood (angwin2023nonoralmanifestationsin pages 1-2, kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6).
• Pretibial hyperpigmentation/hemosiderotic plaques — HP:0001045 Vitiligo is not appropriate; use HP:0001000 Abnormality of skin pigmentation plus a disease-specific descriptor: 83% in the original series and 81% in the 2023 adults (angwin2023nonoralmanifestationsin pages 1-2, kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6).
• Skin fragility — HP:0001030 Fragile skin: 83% originally and 71% in the recent adult cohort (angwin2023nonoralmanifestationsin pages 1-2, kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6).
• Mild skin hyperextensibility — HP:0000974: 73%; abnormal scarring and prominent vasculature each occurred in approximately 50% (kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6).
• Joint hypermobility — HP:0001382, often distal and mild: 44% in the original cohort but 24% in the 2023 adult cohort, demonstrating ascertainment and age/cohort variability (angwin2023nonoralmanifestationsin pages 1-2, kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6).
• Hoarse/vocally altered voice — HP:0001609 Hoarse voice: 38% in the 2023 cohort (angwin2023nonoralmanifestationsin pages 1-2).
• Leukoencephalopathy/white-matter abnormalities — HP:0002352 Leukoencephalopathy: found in 89% of imaged adults in the 2023 series. The denominator was only those imaged, and many lesions appear clinically silent; it should not be interpreted as 89% population prevalence (angwin2023nonoralmanifestationsin pages 1-2).
• Recurrent infection — HP:0002719: approximately 40% in the original cohort (kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6).
• Aneurysm — HP:0002617: approximately 16%; arterial dissection and rare vessel or organ rupture have also been reported (kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6, amberger2023degradationofcollagen pages 1-2).
• Hernia — HP:0000776, acrogeria — HP:0001490, marfanoid facial appearance, poor wound healing, and rare gastrointestinal rupture are recognized but incompletely quantified (kapfererseebacher2016periodontalehlersdanlossyndrome pages 1-2, angwin2023nonoralmanifestationsin pages 1-2).

4. Genetic and molecular information

Causal genes

• C1R — complement C1r; Ensembl ENSG00000159403; MIM 613785.
• C1S — complement C1s; Ensembl ENSG00000182326; MIM 120580.

Open Targets records five C1R and four C1S disease-association evidence items for MONDO:0007527, including PubMed-linked evidence PMID 27745832 for the 2016 gene-discovery paper (published October 2016; DOI 10.1016/j.ajhg.2016.08.019) (OpenTargets Search: periodontal Ehlers-Danlos syndrome-C1R,C1S).

Pathogenic variants and consequences

Reported examples include C1R p.Val50Asp, p.Cys309Trp, p.Cys371Trp, C1R c.1339T>C, p.(Cys447Arg), and C1S p.Cys294Arg and p.Val316del (kapfererseebacher2016periodontalehlersdanlossyndrome pages 3-5, angwin2023nonoralmanifestationsin pages 4-5, bally2019twodifferentmissense pages 1-2). Variant classes are predominantly missense and in-frame deletions/insertions; truncating haploinsufficient alleles are not the characteristic cause.

Variants cluster in or affect CUB and CCP/Sushi domains, subunit interfaces, interdomain hinges, disulfide-forming cysteines, or C1q-binding regions. Functional consequences include local misfolding, abnormal intracellular cleavage, retention or aggregation, failure to integrate normally into the C1 complex, and release of catalytically active fragments (kapfererseebacher2016periodontalehlersdanlossyndrome pages 3-5, grobner2019c1rmutationstrigger pages 1-2, bally2019twodifferentmissense pages 1-2).

For C1S p.Val316del and p.Cys294Arg, both variants produced an identical approximately 40-kDa Fg40 fragment generated by cleavage between Lys353 and Cys354. The fragment retained the serine-protease domain but lacked the N-terminal C1-interaction region, allowing activity to escape normal regulation; it retained esterolytic and HMGB1-cleaving activity but had impaired canonical C4 cleavage (bally2019twodifferentmissense pages 1-2).

All reported disease variants are germline. The 2019 C1S study noted that pathogenic C1S variants were family-specific and absent from ExAC/gnomAD at that time (bally2019twodifferentmissense pages 1-2). Current per-variant gnomAD frequencies and ACMG classifications should be retrieved directly at curation time because databases are updated continuously. No validated modifier gene, protective allele, disease-specific epigenetic signature, recurrent chromosomal abnormality, somatic mechanism, or genetic anticipation is established.

5. Environmental, lifestyle, and infectious information

pEDS is not environmentally caused and is not infectious. Oral dysbiotic plaque bacteria act as local inflammatory stimuli, as in conventional periodontitis, but abnormal host complement/protease regulation makes the response unusually destructive. No specific bacterium, virus, fungus, toxin, pollutant, radiation exposure, diet, alcohol exposure, or occupation has been shown to cause pEDS (liao2022transcriptomeanalysisof pages 1-2, grobner2019c1rmutationstrigger pages 1-2).

Meticulous plaque control, avoidance of smoking, and routine periodontal maintenance are biologically reasonable risk-reduction measures. Their pEDS-specific efficacy has not been quantified in randomized studies.

6. Mechanism and pathophysiology

Ordered causal chain

1. A heterozygous pEDS-associated C1R or C1S variant leads to abnormal folding, intracellular processing, cleavage, secretion, or assembly of C1r/C1s.
2. Abnormal processing leads to intracellular activation of C1r and/or C1s and extracellular release of activated C1s or active proteolytic fragments, often outside the normal C1 complex (demonstrated in transfected cells and patient fibroblasts) (grobner2019c1rmutationstrigger pages 1-2, bally2019twodifferentmissense pages 1-2).
3. Extracellular activated C1s leads to two mechanistic branches:
4. Branch A—immune: cleavage of complement substrates, including C4 in C1R-variant fibroblast experiments, leads to local classical-complement activation without a microbial trigger (demonstrated) (grobner2019c1rmutationstrigger pages 1-2).
5. Branch B—matrix: direct cleavage of type-I collagen and potentially decorin, HMGB1, and MMP9-related substrates leads to accelerated extracellular-matrix turnover (collagen-I cleavage demonstrated; broader substrate contribution partly inferred) (amberger2023degradationofcollagen pages 1-2, bally2019twodifferentmissense pages 1-2).
6. Complement dysregulation plus dental biofilm leads to exaggerated gingival innate inflammation, with monocyte/neutrophil, TNF-α, IL-17, and bacterial-response programs implicated (transcriptomic association; causality not yet proven) (liao2022transcriptomeanalysisof pages 1-2).
7. Inflammation and matrix proteolysis lead to loss of stable collagen organization in attached gingiva, periodontal ligament, skin, and vascular connective tissues (partly demonstrated in fibroblasts and ultrastructure; tissue-level extrapolation remains inferential) (kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6, amberger2023degradationofcollagen pages 1-2).
8. Fragile gingiva and progressive destruction of periodontal ligament and alveolar bone lead to recession, periodontal pockets, tooth mobility, and premature tooth loss (human clinical evidence) (kapfererseebacher2016periodontalehlersdanlossyndrome pages 3-5, kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2).
9. Systemic connective-tissue injury leads to easy bruising, pretibial plaques, skin fragility, abnormal scarring, mild hypermobility, vocal changes, vascular complications, and possibly white-matter abnormalities; the precise mechanism for several non-oral features remains unresolved (angwin2023nonoralmanifestationsin pages 1-2).

Cellular and molecular detail

Functional analysis of 16 C1R variants showed that none integrated normally into C1 in the overexpression system. Patient fibroblast supernatants contained activated C1s and cleaved added C4, whereas control fibroblasts secreted pro-C1s without increased C4 activation (grobner2019c1rmutationstrigger pages 1-2). This supports constitutive complement initiation, not complement deficiency.

The 2023 collagen study found rapid, extensive remodeling of collagen in patient fibroblasts and direct collagen-I degradation by activated C1s. The authors’ central conclusion was that pEDS is “not solely mediated by activation of the complement cascade” but also by inappropriate C1s-mediated matrix degradation (amberger2023degradationofcollagen pages 1-2).

Electron microscopy in human tissues showed reduced collagen content, variable fibril diameters, and abnormal fibril shapes. Conventional fibroblast assays did not consistently demonstrate impaired synthesis or secretion of collagens I, III, or V, supporting excessive turnover rather than defective collagen biosynthesis as the primary lesion (kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6).

Molecular profiling

RNA sequencing of monocytes and gingival fibroblasts from two patients found differential expression only in monocytes. Enrichment involved neutrophil-mediated immunity, response to bacteria, TNF-α and IL-17 pathways; MMP9, VEGFA, IL10, IL1A, IL1B, IL2RA, and IL6 were validated by qPCR and ELISA. The authors described this as the first pEDS transcriptomic dataset, but the sample was too small for diagnostic or prognostic use (liao2022transcriptomeanalysisof pages 1-2).

No replicated proteomic, metabolomic, lipidomic, methylomic, single-cell, spatial-transcriptomic, multi-omics, CRISPR-screen, or organoid study specific to pEDS was identified.

Suggested GO biological processes: classical complement activation (GO:0006958), complement activation (GO:0006956), proteolysis (GO:0006508), collagen catabolic process (GO:0030574), extracellular-matrix organization (GO:0030198), inflammatory response (GO:0006954), neutrophil-mediated immunity (GO:0002446), and response to bacterium (GO:0009617).

Suggested cell types: fibroblast (CL:0000057), monocyte (CL:0000576), neutrophil (CL:0000775), gingival epithelial cell, periodontal-ligament fibroblast, osteoblast (CL:0000062), and osteoclast (CL:0000092). Direct pEDS evidence is strongest for fibroblasts and circulating monocytes.

7. Anatomical structures affected

The primary organ system is the oral cavity/periodontium:

• gingiva and attached gingiva;
• alveolar mucosa;
• periodontal ligament;
• alveolar bone;
• root cementum;
• teeth secondarily lost through periodontal-support failure.

Suggested UBERON annotations include gingiva (UBERON:0001828), oral cavity, tooth, periodontal ligament, cementum, and alveolar bone. The attached gingiva is keratinized tissue tethered to periosteum by type-I collagen; periodontitis progressively damages gingival attachment, periodontal ligament, cementum, and alveolar bone (kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2).

Secondary sites include dermis and subcutaneous tissues, pretibial skin, joints/ligaments, blood-vessel walls, laryngeal/vocal tissues, and cerebral white matter. Disease is generalized rather than lateralized.

At the subcellular level, implicated compartments include the rough endoplasmic reticulum/secretory pathway, extracellular space, complement C1 complex, and collagen-rich extracellular matrix. Suggested GO cellular components are endoplasmic-reticulum lumen (GO:0005788), extracellular region (GO:0005576), collagen-containing extracellular matrix (GO:0062023), and C1 complex (GO:0005602).

8. Temporal development

The disease is lifelong and genetically present from conception. Generalized absence of attached gingiva can be identified in childhood before destructive periodontal disease develops. Only two of 12 variant-positive children, aged 8 and 13, met full 2017 clinical criteria, demonstrating age-dependent ascertainment and the limitations of adult-oriented criteria in children (kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2).

A practical course is:

1. Early/presymptomatic stage: absent attached gingiva, thin fragile gums, easy bruising.
2. Childhood/adolescent stage: plaque-sensitive gingivitis, gingival recession, early attachment and alveolar-bone loss.
3. Progressive stage: rapidly destructive generalized periodontitis, tooth mobility, recurrent periodontal treatment.
4. Advanced stage: partial or complete premature tooth loss; implants or prosthetic rehabilitation may be considered but are challenging.
5. Systemic adult stage: cumulative bruising/pretibial plaques, skin fragility, vocal changes, vascular abnormalities, and detectable white-matter lesions in some patients.

Spontaneous remission has not been established. Periodontal inflammation may be controlled, but lost attachment and bone do not spontaneously regenerate. Childhood is the most important intervention window because attached-gingiva abnormalities precede tooth loss.

9. Inheritance and population

Inheritance is autosomal dominant. Penetrance appeared 100% among identified individuals in the 2019 functional-study summary, although ascertainment bias and age-dependent manifestations should be considered (grobner2019c1rmutationstrigger pages 1-2). Expressivity is variable, particularly for joint, skin, vascular, neurologic, and vocal manifestations.

Prevalence and incidence are unknown. More than 100 patients had been described by 2022, but this is a case count rather than population prevalence (wu2022periodontaldiseaseassociated pages 15-19). No reliable incidence per 100,000, carrier frequency, founder effect, ethnic enrichment, geographic gradient, or sex difference has been established. The 2023 adult cohort’s 5:16 male:female ratio is too small and referral-selected to establish sex bias (angwin2023nonoralmanifestationsin pages 1-2).

Variants are commonly private to individual families; no recurrent C1S founder allele was evident in the 2019 study (bally2019twodifferentmissense pages 1-2). De novo occurrence is possible for any dominant disorder, but its pEDS proportion and germline-mosaicism risk are not quantified. Consanguinity is not etiologically relevant to the usual dominant form.

10. Diagnostics

Clinical criteria

The 2017 classification lists four major criteria:

1. severe, intractable periodontitis of early onset in childhood or adolescence;
2. lack of attached gingiva;
3. pretibial plaques;
4. an affected first-degree relative meeting clinical criteria.

Minor criteria include easy bruising, mainly distal joint hypermobility, skin hyperextensibility/fragility or abnormal scars, recurrent infections, hernias, marfanoid facial features, acrogeria, and prominent vasculature. The original formulation used three major plus one minor criterion; later clinical summaries emphasize that major criterion 1 or 2 plus additional major/minor findings should prompt mandatory molecular confirmation (angwin2023nonoralmanifestationsin pages 1-2, kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2).

Recommended work-up

1. Periodontal examination: gingival phenotype, recession, probing depths, clinical-attachment loss, bleeding/inflammation, tooth mobility, and plaque burden.
2. Dental imaging: panoramic and intraoral radiographs to quantify alveolar-bone loss. Early-onset periodontitis in the discovery study was operationalized in selected families as at least four interproximal sites with attachment loss ≥6 mm and probing depth ≥5 mm, or complete mobility-related tooth loss by age 35 (kapfererseebacher2016periodontalehlersdanlossyndrome pages 1-2).
3. Clinical genetics examination: skin, scars, bruising, pretibial plaques, distal joints, hernias, vascular history, voice, and family pedigree.
4. Molecular testing: sequencing and deletion/duplication analysis of C1R and C1S, preferably within a validated EDS/aggressive-periodontitis panel. A known familial variant can be tested directly.
5. Broader sequencing: EDS/connective-tissue panels or WES/WGS are useful when phenotype is atypical or first-line testing is negative. WES/WGS is not superior to targeted testing for a clearly affected family unless structural, deep-intronic, or alternative diagnoses are suspected.
6. CMA, karyotype, FISH, mitochondrial sequencing, and repeat-expansion testing: not routine because pEDS is a sequence-variant disorder, not a characteristic chromosomal, mitochondrial, or repeat-expansion condition.

There is no validated blood complement level, enzyme assay, collagen biomarker, RNA signature, or biopsy criterion that replaces molecular confirmation. Routine complement assays may be normal; one family showed no consistent systemic classical-pathway abnormality (kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6).

Differential diagnosis

Important differentials include:

• other EDS subtypes, especially classical and vascular EDS—distinguished by their causal genes and absence of the characteristic generalized attached-gingiva defect;
• hypermobile EDS—lacks a known monogenic marker and does not characteristically cause destructive childhood periodontitis;
• Papillon–Lefèvre syndrome (CTSC, autosomal recessive), with palmoplantar keratoderma and severe periodontitis;
• leukocyte-adhesion deficiency, cyclic/severe congenital neutropenia, and other immunodeficiencies with infection-associated periodontitis;
• hypophosphatasia (ALPL), characterized by premature tooth loss with mineralization abnormalities;
• acatalasemia/Takahara disease;
• isolated familial aggressive periodontitis;
• vascular connective-tissue disorders such as Loeys–Dietz or Marfan syndrome when vascular/marfanoid findings dominate.

Screening

Population or newborn screening is not indicated. Cascade testing of first-degree relatives is appropriate once a familial pathogenic variant is known. At-risk children should receive early gingival examination and molecular testing because absence of attached gingiva may precede other criteria.

11. Outcome and prognosis

No robust survival curves, disease-specific mortality rate, or reduction in life expectancy have been published. Most morbidity arises from severe periodontal destruction, premature tooth loss, prosthetic burden, bruising, skin fragility, and occasional vascular or organ complications. Rare arterial aneurysm/dissection or rupture could be life-threatening, but absolute risk is uncertain (kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6, amberger2023degradationofcollagen pages 1-2).

Natural teeth may be lost beginning in early childhood, and complete tooth loss has been reported from adolescence through middle adulthood. Prognosis is variable and likely improved by early diagnosis and intensive periodontal maintenance, although treatment-response percentages are unavailable (kapfererseebacher2016periodontalehlersdanlossyndrome pages 3-5, wu2022periodontaldiseaseassociated pages 15-19).

Potential prognostic indicators are early alveolar-bone loss, uncontrolled plaque inflammation, rapid attachment loss, and prior vascular events. No validated molecular prognostic biomarker or genotype–phenotype calculator exists. The quality-of-life burden has not been quantified with pEDS-specific instruments.

12. Treatment and real-world implementation

There is no approved therapy that corrects C1R/C1S dysregulation. Current management is preventive and supportive:

• Periodontal care: early referral to a periodontist; meticulous home plaque control; frequent professional cleaning and periodontal reassessment; prompt treatment of gingivitis and periodontal pockets; preservation of natural teeth where feasible.
• Dental rehabilitation: restorative dentistry, removable or fixed prostheses, and carefully selected implant therapy. Published clinical experience indicates high peri-implant disease/failure risk, so implants require conservative selection and intensive maintenance (sollazzo2022olliersdisease pages 40-45).
• Antimicrobials: antiseptics or antibiotics may be used for conventional periodontal indications, not as chronic disease-specific therapy. No pEDS response rate is established.
• Surgery/procedures: use atraumatic technique, careful hemostasis and suturing, and anticipate friable gingiva, bruising, and impaired wound healing.
• Musculoskeletal/supportive care: individualized physiotherapy, joint protection, pain management, and occupational therapy when symptomatic.
• Vascular care: baseline specialist assessment and individualized noninvasive surveillance may be considered when there is a personal/family vascular history; evidence does not support a universal pEDS imaging interval.
• Voice/neurologic care: ENT evaluation for persistent hoarseness and neurologic assessment when symptoms accompany white-matter imaging abnormalities.

Suggested NCIT intervention annotations include Genetic Counseling, Genetic Testing, Dental Examination, Periodontal Therapy, Dental Prophylaxis, Antibiotic Therapy, Physical Therapy, and Surgical Procedure. Exact NCIT concept identifiers should be verified against the current terminology release.

Complement inhibitors, C1r/C1s inhibitors, MMP-directed therapy, and matrix-protective approaches are mechanistically attractive but remain experimental. The search identified no pEDS-specific interventional ClinicalTrials.gov study, gene therapy, RNA therapy, cell therapy, CRISPR therapy, or validated pharmacogenomic strategy.

13. Prevention

Primary prevention of the genotype is not possible after conception. Reproductive options include genetic counseling, prenatal diagnosis, and preimplantation genetic testing for a known familial pathogenic variant.

Secondary prevention consists of cascade testing and early oral examination of at-risk children. The prospective pediatric study’s key conclusion was: “Generalized lack of attached gingiva is a pathognomonic feature of pEDS,” and early diagnosis may permit hygiene measures before destructive periodontitis develops (kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2).

Tertiary prevention includes meticulous plaque control, periodontal maintenance, smoking avoidance, prompt infection treatment, tooth-preservation strategies, cautious procedural planning, and surveillance tailored to vascular or other systemic manifestations. Vaccination has no disease-specific preventive role beyond standard immunization schedules.

14. Other species and natural disease

C1R and C1S are evolutionarily conserved complement genes with mammalian orthologs. However, no naturally occurring veterinary disorder conclusively homologous to human C1R/C1S-associated periodontal EDS was identified. EDS-like connective-tissue fragility occurs in domestic animals, but these conditions should not be annotated as pEDS without orthologous molecular evidence. pEDS is noninfectious and has no zoonotic or cross-species transmission potential.

15. Model organisms and experimental systems

The most informative pEDS systems are currently human cellular and biochemical models:

• primary dermal fibroblasts from genetically confirmed patients;
• patient gingival fibroblasts;
• peripheral-blood monocytes;
• HEK293T/HEK293-F cells expressing mutant C1R or C1S;
• recombinant C1s fragments and purified collagen-I proteolysis assays.

These models reproduce abnormal processing, unregulated protease activity, C4 cleavage, inflammatory transcriptional changes, and collagen turnover, but cannot capture the complete oral microbiome, periodontal biomechanics, vascular disease, or longitudinal tooth loss (liao2022transcriptomeanalysisof pages 1-2, amberger2023degradationofcollagen pages 1-2, grobner2019c1rmutationstrigger pages 1-2, bally2019twodifferentmissense pages 1-2).

A 2021 review found engineered mouse or zebrafish models for 14 of 20 EDS-associated genes overall, but the retrieved evidence did not document a validated C1r/C1s pEDS knock-in animal model that recapitulates absent attached gingiva and early tooth loss (vroman2021animalmodelsof pages 1-2). Development of heterozygous knock-in models carrying human gain-of-function alleles would be valuable for testing complement/protease inhibitors and gene-specific interventions.

Evidence quality and current research gaps

The evidence base is dominated by one international discovery cohort, small multicenter phenotype cohorts, family studies, and mechanistic cell/in-vitro experiments. Recent advances are the 2022 monocyte transcriptome study, the 2023 adult systemic-phenotype series, and the 2023 demonstration that activated C1s directly degrades collagen I. Their principal abstract statements respectively report differential expression “only in monocytes,” leukodystrophy in “89% of those imaged,” and that activated C1s “degrades collagen I in cell culture and in in vitro assays” (liao2022transcriptomeanalysisof pages 1-2, angwin2023nonoralmanifestationsin pages 1-2, amberger2023degradationofcollagen pages 1-2).

Major unmet needs are population epidemiology, prospective natural-history data, validated cardiovascular and neurologic surveillance guidance, standardized treatment outcomes, quality-of-life studies, replicated multi-omics, animal models, and trials of complement- or protease-directed treatment. No retrieved 2024 primary study materially changed the established pEDS disease model; the most consequential recent mechanistic evidence remains the March 2023 collagen-I study.

References

1. (kapfererseebacher2016periodontalehlersdanlossyndrome pages 3-5): I. Kapferer-Seebacher, M. Pepin, Roland Werner, T. Aitman, A. Nordgren, H. Stoiber, N. Thielens, C. Gaboriaud, A. Amberger, A. Schossig, R. Gruber, C. Giunta, M. Bamshad, E. Björck, Christina Chen, D. Chitayat, M. Dorschner, Marcus Schmitt-Egenolf, Christopher J. Hale, D. Hanna, H. Hennies, Irene Heiss-Kisielewsky, A. Lindstrand, P. Lundberg, A. Mitchell, D. Nickerson, E. Reinstein, M. Rohrbach, N. Romani, M. Schmuth, R. Silver, F. Taylan, A. Vandersteen, J. Vandrovcova, R. Weerakkody, Margaret Yang, F. Pope, Kirk Zoltan Joszef Herbert Hady James K. Charles N. Usc Aleck Banki Dudas Dumfahrt Haririan Hartsfield Kag, K. Aleck, Z. Bánki, J. Dudas, H. Dumfahrt, H. Haririan, J. Hartsfield, C. Kagen, Uschi Lindert, T. Meitinger, W. Posch, C. Pritz, D. Ross, R. Schroer, G. Wick, R. Wildin, D. Wilflingseder, P. Byers, and J. Zschocke. Periodontal ehlers-danlos syndrome is caused by mutations in c1r and c1s, which encode subcomponents c1r and c1s of complement. American Journal of Human Genetics, 99:1005-1014, Oct 2016. URL: https://doi.org/10.1016/j.ajhg.2016.08.019, doi:10.1016/j.ajhg.2016.08.019. This article has 149 citations and is from a highest quality peer-reviewed journal.

2. (kapfererseebacher2021prospectiveclinicalinvestigations pages 1-2): Ines Kapferer-Seebacher, Elizabeth Oakley-Hannibal, Ulrike Lepperdinger, Diana Johnson, Neeti Ghali, Angela F. Brady, Glenda Sobey, Johannes Zschocke, and Fleur S. van Dijk. Prospective clinical investigations of children with periodontal ehlers–danlos syndrome identify generalized lack of attached gingiva as a pathognomonic feature. Feb 2021. URL: https://doi.org/10.1038/s41436-020-00985-y, doi:10.1038/s41436-020-00985-y. This article has 38 citations and is from a highest quality peer-reviewed journal.

3. (angwin2023nonoralmanifestationsin pages 1-2): C. Angwin, J. Zschocke, T. Kammin, E. Björck, J. Bowen, A. Brady, H. Burns, C. Cummings, R. Gardner, N. Ghali, R. Gröbner, J. Harris, Michael Denis Higgins, D. Johnson, U. Lepperdinger, D. Milnes, F. Pope, R. Sehra, I. Kapferer-Seebacher, G. Sobey, and F. V. van Dijk. Non-oral manifestations in adults with a clinical and molecularly confirmed diagnosis of periodontal ehlers-danlos syndrome. Frontiers in Genetics, May 2023. URL: https://doi.org/10.3389/fgene.2023.1136339, doi:10.3389/fgene.2023.1136339. This article has 10 citations and is from a peer-reviewed journal.

4. (grobner2019c1rmutationstrigger pages 1-2): Rebekka Gröbner, Ines Kapferer-Seebacher, Albert Amberger, Rita Redolfi, Fabien Dalonneau, Erik Björck, Di Milnes, Isabelle Bally, Veronique Rossi, Nicole Thielens, Heribert Stoiber, Christine Gaboriaud, and Johannes Zschocke. C1r mutations trigger constitutive complement 1 activation in periodontal ehlers-danlos syndrome. Frontiers in Immunology, Nov 2019. URL: https://doi.org/10.3389/fimmu.2019.02537, doi:10.3389/fimmu.2019.02537. This article has 49 citations and is from a peer-reviewed journal.

5. (liao2022transcriptomeanalysisof pages 1-2): Zhuoyi Liao, Tian Zhao, Ningxiang Wang, Jiaqi Chen, Weibin Sun, and Juan Wu. Transcriptome analysis of monocytes and fibroblasts provides insights into the molecular features of periodontal ehlers-danlos syndrome. Frontiers in Genetics, Apr 2022. URL: https://doi.org/10.3389/fgene.2022.834928, doi:10.3389/fgene.2022.834928. This article has 1 citations and is from a peer-reviewed journal.

6. (amberger2023degradationofcollagen pages 1-2): Albert Amberger, Johanna Pertoll, Pia Traunfellner, Ines Kapferer-Seebacher, Heribert Stoiber, Lars Klimaschewski, Nicole Thielens, Christine Gaboriaud, and Johannes Zschocke. Degradation of collagen i by activated c1s in periodontal ehlers-danlos syndrome. Frontiers in Immunology, Mar 2023. URL: https://doi.org/10.3389/fimmu.2023.1157421, doi:10.3389/fimmu.2023.1157421. This article has 12 citations and is from a peer-reviewed journal.

7. (kapfererseebacher2016periodontalehlersdanlossyndrome pages 1-2): I. Kapferer-Seebacher, M. Pepin, Roland Werner, T. Aitman, A. Nordgren, H. Stoiber, N. Thielens, C. Gaboriaud, A. Amberger, A. Schossig, R. Gruber, C. Giunta, M. Bamshad, E. Björck, Christina Chen, D. Chitayat, M. Dorschner, Marcus Schmitt-Egenolf, Christopher J. Hale, D. Hanna, H. Hennies, Irene Heiss-Kisielewsky, A. Lindstrand, P. Lundberg, A. Mitchell, D. Nickerson, E. Reinstein, M. Rohrbach, N. Romani, M. Schmuth, R. Silver, F. Taylan, A. Vandersteen, J. Vandrovcova, R. Weerakkody, Margaret Yang, F. Pope, Kirk Zoltan Joszef Herbert Hady James K. Charles N. Usc Aleck Banki Dudas Dumfahrt Haririan Hartsfield Kag, K. Aleck, Z. Bánki, J. Dudas, H. Dumfahrt, H. Haririan, J. Hartsfield, C. Kagen, Uschi Lindert, T. Meitinger, W. Posch, C. Pritz, D. Ross, R. Schroer, G. Wick, R. Wildin, D. Wilflingseder, P. Byers, and J. Zschocke. Periodontal ehlers-danlos syndrome is caused by mutations in c1r and c1s, which encode subcomponents c1r and c1s of complement. American Journal of Human Genetics, 99:1005-1014, Oct 2016. URL: https://doi.org/10.1016/j.ajhg.2016.08.019, doi:10.1016/j.ajhg.2016.08.019. This article has 149 citations and is from a highest quality peer-reviewed journal.

8. (OpenTargets Search: periodontal Ehlers-Danlos syndrome-C1R,C1S): Open Targets Query (periodontal Ehlers-Danlos syndrome-C1R,C1S, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

9. (wu2022periodontaldiseaseassociated pages 15-19): Juan Wu, Wai Keung Leung, and Weibin Sun. Periodontal disease associated with genetic disorders. Dentistry, Feb 2022. URL: https://doi.org/10.5772/intechopen.97497, doi:10.5772/intechopen.97497. This article has 1 citations.

10. (kapfererseebacher2016periodontalehlersdanlossyndrome pages 5-6): I. Kapferer-Seebacher, M. Pepin, Roland Werner, T. Aitman, A. Nordgren, H. Stoiber, N. Thielens, C. Gaboriaud, A. Amberger, A. Schossig, R. Gruber, C. Giunta, M. Bamshad, E. Björck, Christina Chen, D. Chitayat, M. Dorschner, Marcus Schmitt-Egenolf, Christopher J. Hale, D. Hanna, H. Hennies, Irene Heiss-Kisielewsky, A. Lindstrand, P. Lundberg, A. Mitchell, D. Nickerson, E. Reinstein, M. Rohrbach, N. Romani, M. Schmuth, R. Silver, F. Taylan, A. Vandersteen, J. Vandrovcova, R. Weerakkody, Margaret Yang, F. Pope, Kirk Zoltan Joszef Herbert Hady James K. Charles N. Usc Aleck Banki Dudas Dumfahrt Haririan Hartsfield Kag, K. Aleck, Z. Bánki, J. Dudas, H. Dumfahrt, H. Haririan, J. Hartsfield, C. Kagen, Uschi Lindert, T. Meitinger, W. Posch, C. Pritz, D. Ross, R. Schroer, G. Wick, R. Wildin, D. Wilflingseder, P. Byers, and J. Zschocke. Periodontal ehlers-danlos syndrome is caused by mutations in c1r and c1s, which encode subcomponents c1r and c1s of complement. American Journal of Human Genetics, 99:1005-1014, Oct 2016. URL: https://doi.org/10.1016/j.ajhg.2016.08.019, doi:10.1016/j.ajhg.2016.08.019. This article has 149 citations and is from a highest quality peer-reviewed journal.

11. (angwin2023nonoralmanifestationsin pages 4-5): C. Angwin, J. Zschocke, T. Kammin, E. Björck, J. Bowen, A. Brady, H. Burns, C. Cummings, R. Gardner, N. Ghali, R. Gröbner, J. Harris, Michael Denis Higgins, D. Johnson, U. Lepperdinger, D. Milnes, F. Pope, R. Sehra, I. Kapferer-Seebacher, G. Sobey, and F. V. van Dijk. Non-oral manifestations in adults with a clinical and molecularly confirmed diagnosis of periodontal ehlers-danlos syndrome. Frontiers in Genetics, May 2023. URL: https://doi.org/10.3389/fgene.2023.1136339, doi:10.3389/fgene.2023.1136339. This article has 10 citations and is from a peer-reviewed journal.

12. (bally2019twodifferentmissense pages 1-2): Isabelle Bally, Fabien Dalonneau, Anne Chouquet, Rebekka Gröbner, Albert Amberger, Ines Kapferer-Seebacher, Heribert Stoiber, Johannes Zschocke, Nicole M. Thielens, Véronique Rossi, and Christine Gaboriaud. Two different missense c1s mutations, associated to periodontal ehlers-danlos syndrome, lead to identical molecular outcomes. Frontiers in Immunology, Dec 2019. URL: https://doi.org/10.3389/fimmu.2019.02962, doi:10.3389/fimmu.2019.02962. This article has 23 citations and is from a peer-reviewed journal.

13. (sollazzo2022olliersdisease pages 40-45): V Sollazzo and V Sollazzo. Ollier's disease. Unknown journal, 2022.

14. (vroman2021animalmodelsof pages 1-2): Robin Vroman, Anne-Marie Malfait, Rachel E. Miller, Fransiska Malfait, and Delfien Syx. Animal models of ehlers–danlos syndromes: phenotype, pathogenesis, and translational potential. Frontiers in Genetics, Oct 2021. URL: https://doi.org/10.3389/fgene.2021.726474, doi:10.3389/fgene.2021.726474. This article has 26 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0007527 (3 mentions) - the report calls it "if available"; MONDO calls it Ehlers-Danlos syndrome, periodontitis type

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• HP:0001490 (1 mention) - HP does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0062023 (obsolete collagen-containing extracellular matrix) (1 mention) - replaced by GO:0031012